Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks
K+S Raises 2026 Earnings Outlook After Strong Q1 Results
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 



